Medicare Enrollment Approved for Plus Therapeutics' CNSide Diagnostic, Paving Way for Reimbursement
summarizeSummary
Plus Therapeutics has received Medicare enrollment approval for its CNSide diagnostic, enabling the company to submit claims for its CNSide CSF Assay Platform with a CPT code 0640U payment rate effective July 1, 2026. This is a significant positive development, especially for a company that recently disclosed substantial net losses and going concern doubts in its last 10-K. The approval provides a clear path to reimbursement for a key product, expanding market access beyond the recent Blue Shield of California agreement. This move is crucial for generating much-needed revenue and improving the company's financial stability. Traders will be watching for updates on actual revenue generation from CNSide after the July 1 billing date and its impact on the company's overall financial health.
At the time of this announcement, PSTV was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.2M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.